Reaktion #73906

ord-59f18ed4145f4d2b8d5b32a8a2036756

Reaktionsbedingungen

Detaillierte Bedingungen
See reaction.notes.procedure_details.

Aufarbeitung

  1. 1
    SonstigeThe phases were separated
  2. 2
    Waschenthe organic phase was washed with 1N hydrochloric acid (30 ml) and brine (30 ml)
  3. 3
    TrocknenThe organic phase was dried over MgSO4
  4. 4
    Sonstigeevaporated in vacuo
  5. 5
    SonstigeThe residue was purified by Biotage™ flash column chromatography
  6. 6
    Wascheneluting with 3:2 ethyl acetate
  7. 7
    Sonstigeevaporated in vacuo

Vorschrift

(2RS)-2-(1-benzothien-5-yl)-2-[(3R,6R)-3-(2,3-dihydro-1H-inden-2-yl)-6-isobutyl-2,5-dioxopiperazin-1-yl]-N-(2-benzyloxyphenyl)ethanamide (1.0 g) was dissolved in dichloromethane (5 ml) and to this was added dropwise a 1.0M solution of BBr3 in dichloromethane (2.0 ml). The reaction mixture was stirred at room temperature for 2 hours. To the reaction mixture was added 1N hydrochloric acid (30 ml) and dichloromethane (20 ml). The phases were separated and the organic phase was washed with 1N hydrochloric acid (30 ml) and brine (30 ml). The organic phase was dried over MgSO4 and evaporated in vacuo. The residue was purified by Biotage™ flash column chromatography, eluting with 3:2 ethyl acetate:cyclohexane. The required fractions were combined and evaporated in vacuo to give (2RS)-2-(1-benzothien-5-yl)-2-[(3R,6R)-3-(2,3-dihydro-1H-inden-2-yl)-6-isobutyl-2,5-dioxopiperazin-1-yl]-N-(2-hydroxyphenyl)ethanamide (210 mg).

Quelle

DOI: 10.6084/m9.figshare.5104873.v1Patent: US08541579B2uspto-grants-2013_09